_ash-2016-multiple-myeloma-highlights.jpg "ASH 2016: Multiple myeloma highlights from selinexor mm Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 9 min 93 sec
✓ Published: 17-Mar-2017
✓ Published: 17-Mar-2017
Description:
Prof Marivi Mateos (University Hospital of Salamanca, Salamanca, Spain) chairs an expert discussion on the latest in Multiple Myeloma (MM) for ecancertv at ASH 2016 in San Diego.nnWith Prof Philippe Moreau (University Hospital of Nantes, Nantes, France), Prof Saad Usmani (Carolinas Healthcare System, Charlotte, USA) and Prof Heinz Ludwig (Wilhelminenspital, Center for Oncology and Hematology, Vienna, Austria).nnThe discussion started by looking at newly diagnosed multiple myeloma patients, with
Prof Marivi Mateos (University Hospital of Salamanca, Salamanca, Spain) chairs an expert discussion on the latest in Multiple Myeloma (MM) for ecancertv at ASH 2016 in San Diego.nnWith Prof Philippe Moreau (University Hospital of Nantes, Nantes, France), Prof Saad Usmani (Carolinas Healthcare System, Charlotte, USA) and Prof Heinz Ludwig (Wilhelminenspital, Center for Oncology and Hematology, Vienna, Austria).nnThe discussion started by looking at newly diagnosed multiple myeloma patients, with
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_once-weekly-selinexor-carfilzomib-and-dexamethasone-xkdin-carfilzomib-non-refractory-multiple-myeloma-mm-patients.webp "Prof Cristina Gasparetto speaks to ecancer about the efficacy of once weekly selinexor, carfilzomib, and dexamethasone (XKD)in carfilzomib non-refractory multiple myeloma (MM) patients. nnInitially, she explains the background of this study. Prof Gasparetto then talks about the methodology and key results of this study. nnIn patients with heavily pretreated MM, weekly XKd is highly active with an ORR of 78% and deep responses (≥VGPR 48%) with an overall PFS of 23 months. All AEs, including gra")
⏲ 4 min 69 sec ✓ 25-Jun-2021
_all-about-xpovio-selinexor.webp "HealthTree University Myeloma")
_mechanism-of-action-of-selinexor-for-the-treatment-of-multiple-myeloma.webp "Targeted Oncology")
_selinexor-a-clear-role-in-heavily-pre-treated-multiple-myeloma.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
_how-long-will-i-live-with-multiple-myeloma-and-is-there-a-cure.webp "HealthTree University Myeloma")
_expert-panel-discussion-on-the-use-of-novel-therapies-in-multiple-myeloma.webp "World Myeloma Forum Expert Panel members Sagar Lonial, MD; Suzanne Lentzsch, MD, PhD; Ravi Vij, MD, MBA; and Ola Landgren, MD, PhD discuss data presented at ASH 2017 on the use of Novel Therapies in Multiple Myeloma.nnThe panel discusses four (4) abstracts presented at ASH using Novel Therapies including Venetoclax, GSK2857916, and Selinexor and their implication in the management of patients with Multiple Myeloma:nnAbstract 3131: Phase 1 Study of Venetoclax in Combination with Dexamethasone As")
⏲ 5 min 75 sec ✓ 23-Jan-2018
_medical-stories-multiple-myeloma-kenny39s-story.webp "Medical Stories")
_once-weekly-selinexor-carfilzomib-and-dexamethasone-xkdin-carfilzomib-non-refractory-multiple-myeloma-mm-patients.jpg)
_all-about-xpovio-selinexor.jpg)
_mechanism-of-action-of-selinexor-for-the-treatment-of-multiple-myeloma.jpg)
_selinexor-a-clear-role-in-heavily-pre-treated-multiple-myeloma.jpg)
_how-long-will-i-live-with-multiple-myeloma-and-is-there-a-cure.jpg)
_expert-panel-discussion-on-the-use-of-novel-therapies-in-multiple-myeloma.jpg)
_medical-stories-multiple-myeloma-kenny39s-story.jpg)
![[+]](/images/menu.gif){kind=small}